The resurgence of psychedelic research over the past two decades has yielded promising results for the treatment of numerous mental health conditions such as anxiety, addiction and PTSD. Upon ingestion of prodrug psilocybin, the most widely studied psychedelic molecule, it is metabolized to psilocin the active metabolite responsible for delivering therapeutic benefit. Thus, it would make sense to administer psilocin directly to, reduce the onset time of action,  enhance dose consistencies, and provide improved delivery methods such as transdermal and/or sublingual.

However, psilocin’s chemical and physical stability limitations have hampered its development.  In attempts to overcome these molecular challenges, organic salts of psilocin are being created to provide the necessary chemical enhancements. These new inventions are also protectable providing additional benefit to the technical discoveries through the filing of intellectual property. Herein, 3 novel salts of psilocin (all GRAS counterions) have been created and patents (US and PCT) filed.